{"ticker": {"uuid": "f30a8a10-9a7e-4631-a859-b6566bc1648b", "symbol": "ASRT", "name": "Assertio Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Press Release: Assertio Provides Update on Garda Therapeutics Tender Process", "summary": "Assertio Holdings, Inc. announced an update regarding the tender offer for all outstanding shares of Garda Therapeutics Inc. The tender offer period, which began on March 29, 2023, has been extended several times and is now set to expire on July 24, 2026. As of July 10, 2026, app", "url": "https://www.moomoo.com/news/post/68640102/press-release-assertio-provides-update-on-garda-therapeutics-tender-process?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T07:11:51", "published_display": "13 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Small-Cap Growth Virtual Investor Conference Summary", "summary": "This summary details Assertio Holdings Inc.'s financial performance and strategic outlook discussed at the Small-Cap Growth Virtual Investor Conference on February 1, 2026. The company reported strong Q1 financials, reaffirmed its 2024 guidance, and highlighted Rolvedon as its pr", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-small-cap-growth-virtual-investor-conference_onXvfO3d", "source_name": "Quartr", "published_at": "2026-07-11T00:39:37", "published_display": "11 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Proxy Filing Summary", "summary": "Assertio (ASRT) has released a summary of its Proxy Filing for an Annual Meeting scheduled for May 7, 2025. Key topics for the meeting include the election of seven directors, approval of an amendment to the 2014 Omnibus Incentive Plan, an advisory vote on executive compensation,", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-proxy-filing_onXvqJZF", "source_name": "Quartr", "published_at": "2026-07-10T17:10:55", "published_display": "10 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Maxim Group\u2019s 2024 Healthcare Virtual Summit Summary", "summary": "This article summarizes Assertio's (ASRT) presentation at Maxim Group\u2019s 2024 Healthcare Virtual Summit, highlighting the company's strategic shift from a broad portfolio to a focus on 7 key assets, with Rolvedon as the primary growth driver. Assertio aims to expand Rolvedon's mar", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-maxim-group-s-2024-healthcare-virtual-summit_onXvfEB8", "source_name": "Quartr", "published_at": "2026-07-09T00:39:37", "published_display": "09 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Q4 2025 earnings summary", "summary": "Assertio (ASRT) reported its Q4 and full-year 2025 earnings, exceeding guidance for net product sales and adjusted EBITDA under new leadership. The company is refocusing on ROLVEDON as its core growth asset, completing its integration and optimizing commercial infrastructure for ", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-q4-2025_onXvqPnY", "source_name": "Quartr", "published_at": "2026-07-09T00:39:37", "published_display": "09 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Q1 2026 earnings summary", "summary": "Assertio (ASRT) reported its Q1 2026 earnings, detailing the sale of non-ROLVEDON assets for $35M and a merger agreement with Garda Therapeutics. The company experienced a significant revenue decline to $9.9M, leading to a net loss of $18.9M, primarily due to lower ROLVEDON and I", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-q1-2026_onXvnkCb", "source_name": "Quartr", "published_at": "2026-07-09T00:39:37", "published_display": "09 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 26, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Q4 2024 earnings summary", "summary": "Assertio (ASRT) reported its Q4 and full-year 2024 earnings, highlighting a stabilization year with Rolvedon sales exceeding $60 million and optimized portfolio management resulting in over $26 million in operating cash flow. The company strengthened its balance sheet and made le", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-q4-2024_onXvfBGz", "source_name": "Quartr", "published_at": "2026-07-08T12:10:55", "published_display": "08 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings (NASDAQ: ASRT) common stock struck from Nasdaq list", "summary": "Assertio Holdings, Inc. (ASRT) common stock has been removed from listing and registration on the Nasdaq Stock Market LLC, as indicated by a Form 25 SEC filing. This voluntary withdrawal means the exchange and issuer complied with rules governing such removal due to Section 12(b)", "url": "https://www.stocktitan.net/sec-filings/ASRT/25-nse-assertio-holdings-inc-sec-filing-53b125ecbd98.html", "source_name": "Stock Titan", "published_at": "2026-07-07T14:39:53", "published_display": "07 Jul 2026 14:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Deadline Alert", "summary": "Faruqi & Faruqi, LLP is investigating potential claims against Assertio Holdings, Inc. (NASDAQ: ASRT) and reminds investors of a March 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Assertio made false or", "url": "https://www.newsfilecorp.com/release/196039/Assertio-Deadline-Alert?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-07T11:40:39", "published_display": "07 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASRT CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds Assertio Holdings, Inc. (ASRT) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm", "summary": "Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against Assertio Holdings, Inc. (NASDAQ: ASRT), citing violations of federal securities laws due to alleged omissions and fraudulent misrepresentations. The lawsuit stems from significant stock price d", "url": "https://www.newsfilecorp.com/release/195846/ASRT-CLASS-ACTION-NOTICE-Kessler-Topaz-Meltzer-Check-LLP-Reminds-Assertio-Holdings-Inc.-ASRT-Shareholders-of-Securities-Fraud-Class-Action-Lawsuit-and-Encourages-Investors-with-Substantial-Losses-to-Contact-the-Firm?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-05T11:10:57", "published_display": "05 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Lifesciences Completes Acquisition of Assertio Holdings", "summary": "Zydus Lifesciences has successfully completed its tender offer for the acquisition of Assertio Holdings Inc., marking a strategic expansion into the US pharmaceutical market. Assertio shareholders received $23.50 per share in cash, and Assertio will become a wholly-owned subsidia", "url": "https://themachinemaker.com/zydus-lifesciences-completes-acquisition-of-assertio-holdings/", "source_name": "Machine Maker", "published_at": "2026-06-29T20:40:08", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[15-12G] Assertio Holdings, Inc. SEC Filing", "summary": "Assertio Holdings, Inc. has filed Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports under Sections 13 and 15(d). The filing, dated June 26, 2026, was s", "url": "https://www.stocktitan.net/sec-filings/ASRT/15-12g-assertio-holdings-inc-sec-filing-dbe79f6fbba2.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:40:49", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Assertio Holdings, Inc. SEC Filing", "summary": "This article reports on an SEC filing (Form EFFECT) by Assertio Holdings, Inc. (ASRT), which received a neutral impact and sentiment rating. The filing indicates an effectiveness date of June 17, 2026, for a Notice of Effectiveness related to access number 0001104659-26-074620. A", "url": "https://www.stocktitan.net/sec-filings/ASRT/effect-assertio-holdings-inc-sec-filing-572d5f4cf6f1.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:59", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus\u2019s acquisition of Assertio to bolster its specialty pharma presence in US market", "summary": "Zydus Lifesciences Ltd. has completed its cash tender offer to acquire U.S.-based Assertio Holdings, Inc. for $23.50 per share. Upon finalization, Assertio will become a wholly-owned subsidiary of Zydus and will be delisted from Nasdaq. This acquisition aims to strengthen Zydus' ", "url": "https://www.indianpharmapost.com/news/zyduss-acquisition-of-assertio-to-bolster-its-specialty-pharma-presence-in-us-market-20664", "source_name": "Indian Pharma Post", "published_at": "2026-06-20T05:09:42", "published_display": "20 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings Inc (ASRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article details the revenue breakdown for Assertio Holdings Inc (ASRT), providing insights into its performance by business segment and geographical region. The company's revenue streams are primarily driven by products like ROLVEDON, INDOCIN, and Sympazan, with the United S", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asrt/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:12", "published_display": "18 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings Inc (ASRT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Assertio Holdings Inc (ASRT), listing major institutional shareholders like Nantahala Capital Management and Opaleye Management, along with their respective holdings. It also breaks down shareholder types, institutional shareholdi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asrt/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:12", "published_display": "18 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings Inc (ASRT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Assertio Holdings Inc (ASRT), noting its current earnings forecast score, average price target of $3.00, and analyst ratings. It also includes a peer comparison and answers FAQs regarding revenue expectations, price targets, recent EP", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asrt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:12", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Completes USD 166.4 Million Acquisition of US-Based Assertio Holdings", "summary": "Zydus Lifesciences has completed its acquisition of US-based Assertio Holdings Inc. for $166.4 million. Through its wholly-owned subsidiary, Zara Merger Sub Inc, Zydus successfully concluded the cash tender offer for all outstanding shares of Assertio. As a result, Assertio is no", "url": "https://medicaldialogues.in/amp/news/industry/pharma/zydus-completes-usd-1664-million-acquisition-of-us-based-assertio-holdings-173050", "source_name": "Medical Dialogues", "published_at": "2026-06-17T16:06:00", "published_display": "17 Jun 2026 16:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) director fully cashes out shares and options in Zydus $23.50-per-share merger", "summary": "Assertio Holdings, Inc. director William McKee has fully disposed of his equity, including 27,936 shares of common stock and two stock option grants, as part of the company's cash sale to Zydus. A Zydus subsidiary acquired all outstanding Assertio shares at $23.50 per share, lead", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-36675b4dbec9.html", "source_name": "Stock Titan", "published_at": "2026-06-17T15:39:52", "published_display": "17 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) director cashes out shares and options in Zydus merger", "summary": "Assertio Holdings director Heather L. Mason has disposed of all her equity in Assertio following its merger with Zydus entities. Her common shares and eligible stock options were cashed out at $23.50 per share through a tender offer that became effective on June 16, 2026. The For", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-1755c56833ac.html", "source_name": "Stock Titan", "published_at": "2026-06-17T04:40:26", "published_display": "17 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus buys Assertio (ASRT); EVP Schlessinger equity cashed out at $23.50", "summary": "Assertio Holdings, Inc.'s EVP and General Counsel, Sam Schlessinger, cashed out all his equity, including common shares, stock options, and restricted stock units, as part of the company's merger with Zydus Worldwide DMCC. Zydus successfully completed a tender offer for Assertio'", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-13f82ad09665.html", "source_name": "Stock Titan", "published_at": "2026-06-17T04:10:14", "published_display": "17 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) COO exits stock, options and RSUs in $23.50-per-share cash merger", "summary": "Assertio Holdings, Inc.'s President and COO, Paul Schwichtenberg, reported the disposition of his equity awards following the company's merger with Zydus entities. The merger, which made Assertio a wholly-owned subsidiary, involved a tender offer where all common shares were acqu", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-ee569b458752.html", "source_name": "Stock Titan", "published_at": "2026-06-17T02:35:33", "published_display": "17 Jun 2026 02:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO Ajay Patel exits Assertio (ASRT) stake in $23.50-per-share merger", "summary": "Assertio Holdings, Inc. CFO Ajay Patel has exited all his equity holdings in the company, including 15,942 common shares and various stock options and restricted stock units, as part of Assertio's cash merger with Zydus entities. The merger involved a tender offer of $23.50 per s", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-24d25004d068.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:34", "published_display": "16 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) director\u2019s shares and options cashed out in $23.50 Zydus buyout", "summary": "Assertio Holdings, Inc. director Sravan Kumar Emany reported that all his equity in the company, including 23,855 shares and various stock options, was cashed out as part of Assertio's merger with Zydus Worldwide DMCC. The common shares were disposed of at the tender offer price ", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-cb24c71f5837.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:34", "published_display": "16 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) CEO exits all shares and awards in $23.50-per-share cash merger", "summary": "Assertio Holdings, Inc. CEO Mark L. Reisenauer disposed of all his equity interests in connection with Assertio\u2019s cash merger with an affiliate of Zydus. A tender offer acquired all outstanding Assertio common shares at $23.50 per share in cash, resulting in the cancellation and ", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-f1857afd104f.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:34", "published_display": "16 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings (ASRT) director exits as Zydus cash merger pays $23.50", "summary": "Assertio Holdings director Kirk Sigurd has disposed of all his equity in the company following its merger with Zydus. His 12,017 common shares were converted to cash at $23.50 per share, and all stock options were either cashed out or cancelled according to the merger terms. This", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-ce2fe455261e.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:34", "published_display": "16 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acquirer completes Assertio deal; ASRT removed registered shares after $23.50 tender", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNNmJzczdSakpsUUsyN1VrTk1TRUh2UW9mMkdIZjd3VWUtelVxX0wzSVF5dGRGelBuQ2tqRy13RFVCSHo4LTRBejZ6MUJMQUZZSDExdDZ0RE1vc1g1OGtPVlpMZVc5d2VQQ2xuWTUwZE93WENRZkFxMHNud3ZVYk5QQWhiQy1fQVpaeFhUWlR0RlZKdGdldWZncVdrNXlHdzh2Ympv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus deal gives Assertio holders $23.50 cash per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQcEVxME5CMUt6c3kzZ3FZU3NkWEpxalhncXB1N0ZmOUV6dlBxVExuLURqNVJ6UEt5aFR6Vm52TmhCLUVoS3FWaGhVNGNCXzM0S1dJY1hDcmRRc2hSLWgzYk9MY3hVbi00WVBkQWU1U2RYeG1aYl9RSk5vaEY0Q1ZIOEpDS2JnVDNzbFZhcXlDREZsdmZDNE44a2wwbmo0bFNlNjg5NzdQaEE3ZS1XVG4yLU5tajBJc2czVTMyQzdRVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Lifesciences (NASDAQ: ASRT) completes $23.50-per-share tender offer", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPLVhFUTZLT2xnTHdGdWU5enVxaUNzUldTbFdnNzAwWG53QkhHbWFWbnFTOWJlYWVrc1RVa1g4N3pFZ25YRkZ2Z0p4OUJLM0RVbDBlZGpXT3dvZEhaYklLcUpHUldJTzVPeUZZSGpxLUtGYmVONm12bkdJVmJmZ1JEeVEzRHEwbl9pclljMGY3OGgtVE5sMHp1T2NPMzRfTDBqUHRsT2EyYUFDZVZpUEdoOU94dHJxZ2ktMURRaFIzQnVRT3It?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio investors get 75.8% premium in $166.4M Zydus buyout", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcUJlMFczWTZKZzlhS25Wbnp4Wkl1bVRRQVBLTGJOYnQ0cVdsc0NKZnJIdVNsOXBQUW4tS1R3QUQzSmlaaWhtcEwtUmx2bHpUa0t6WEswTm9LWlRqUnp2VzE4Z1ZCZ3BOaW5wbFp5SGxnMGg0YkM2WVk3RFVKNVgyUVZIcUI2OGtHUHRNOTBtRXdIRDIxd1ZSTUpNTGFYUlRJVHd2a2pBSVI4Z0owSUVxdXc4cXdxQ01TaXVkTkRvcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOTDdvdTNTZG0zWmQxT0h2Ql9TNmo5UDk1ZVRnQVVZTHBHOGd3QmhpYlNRVVlmajladmFxV1ZLU091b1JWNzEwaWEtcEdwaGNKaV94cGEwbWw2cmJGU3c2TEdfRWJvQTFYV3N3RE1DaWV3TzhJTmdIUGZWa1YtOVJQQ2NXV3dxS3J5aUNQdndHd24zdE0?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Assertio (ASRT) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOVFlPU01VamJXTmJXcU9MREJRLTVOaXBKWkh5MEdURFhLZ25ONHNHWkUzd0M4aDJaUFhOajR0OTlzbmVuSmZ2WDRnYjVYcS01NXltRjh3eENqM0pHUXlOck5WRDZjRFJsU3VOU1lXOU9MSFBwb0QxVm1ENkpUZE41SEdzRWlROUM3YXU3ZW1UWjdGYnkwSzRnRmFGblZoNFRCODhV?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Assertio Holdings (ASRT) Story Is Shifting With The Takeover And Reset Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPekRyMkNaU3VIaXIyZmlIQzRQVFI4NjMtREdzQmhMSmg5REpfOW5fd1FaOFdncWxLWVFuM21DRk5GeHJJelNpMjhXaE5JTmIyWWRkUjdOOW5WTmMwQncxOW1XTDRtT1hzOXhfTFp5NktZUHZtOTdLRHBlaG4yQzJkSGVJTnNLZmMxb21XWUFHNUJJNWJxTlNtdEFSSTRWbU5uOGxaUA?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASRT Stock Alert: Halper Sadeh LLC is Investigating Whether Assertio Holdings, Inc. is Obtaining a Fair Price for its Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxQQlF1MnhTZ0IzNTJleDlSNWVDaGM3MUtXXzFDOUszYlNEa0M1NFVoVTJCamF2UVlJMlcwOXprTXRzS1VLX21fSXd2WWZYTW5Mc01oSlZwVnB1SVFNcFlpbV94Vm12U1pBYzdoVm5EX0Y1WE5wS0RmNUFkWTMtdTF3bXhfY2M0cmFIZnBQb1l2WjFBUHBaQXJJTGU5NDdwVGd2bDRZMGUyV0cxUTd5TnNFdEF1NXpEQmlyXzJtdHZHY0ZRamZzdUFod2ZVcjlDc2pmaEZMbmVnR2I1MFdoQVJUeGhEMjkxM0I0Z0VOWE9tWl9FWVBwNHNONjQ3MDdobUpNVWZvNXptVFBJVmZYeWdKdGhWaw?oc=5", "source_name": "Business Wire", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQTXA2dnNQYU5aOXVJYUVBQ2g3OC0weldPMkMwYmpTemZKSlVvTVdhT2JkT0lyMDNybzFvb0M0UGpNTnd0dXotNjUwNWNoR2Y5RVV4WTRodFFOTFBhMzgwOVVLTmpvTXNTTFNEM0pVaHR0SndJbkFTd2paYzdGVXZWMm5qMzlxbllGa2paVUtlT2xRdW55UHJ4QlJGSTBuUWRf?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street cuts Assertio stock rating on acquisition deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPU1NIWFh6ZU1SQWsteEotM1Z2bHZ6RFZEcmk0cXgwVlJDWkZBQWtSVUNqcXdFYmxybk92UXVpYUdVOHR4QTZLZFJ2QXJWa2lTTHo4TXBoTXJ2aWNXM2U4alNUUVgtanlpZFVFQWE0SWdtMzZmeTU5aHhFTmJUR2VWREFHeXBRYnYzVDRJRmlLRTg2SUNER0lCYmp0czJoZ2QtMWNIUnJkM0tFdG5wdkhJeFd3Tlh3bnlvS2c?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Assertio stock rating on Garda acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxONVYzZEl1eFEyRENwMVFJQWowY2dMUnVtczA5alpYN0l4dzZ0WDVlRjdiOEJWSjRTcUEyRFp1SFVOZEt4QVk0R3BRMVdXZjlRTWpZNHZVZkV1N0xiRGY4bnRBdFNvel9wVTJGY0ZDWEJOb3VGakFQU3pfVlRsakpXNERZWDYteTRjLXh4RWxyUUJMRXFCdEJ4MUl3b29hR09uejRkTDBGRWI3STZiZVpOOXRqVlVRcHpQd3V2R0ZB?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings (ASRT) Issues 2026 Sales Guidance After Wider 2025 Losses Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQSjBFNWZtTkZyYXBqa2lVd3Bkem1IOC1xTE4zUUV1U2d0Sm1NdjZlQWtUdkZWRGN4Z0xtWHU0RmVUQXZDVVVjaW1JbjNFZ1NfNUdyMmJqeHN0Y2ljWEpzR3ZscnN4ZVBKRHdwMU54T1JXcExsOVlwS2Eya0RtOGE5UE9Cb1Jxam1fbWVRSFpsb3dqbTd0Ni1fREZ4YWNzRVJ3?oc=5", "source_name": "Market source", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPcFoyZ3BkOXZubThKZk1KeWNxaEpSVUdfZkN0TWIxX2lvbnVhY0lGQkNvNzRVUm4yOXJpMU9pQ3VjYzdFYUI1QmpEaEJsSmRfSjFFQ2ZFVi1OSWtmdGZmREI1WFdqQ2RKMWV0dDdxNzlWODJvSnhERzN4dGRheUs3cExQWm5OX2xGTlZXWDNhZ2owNDlz?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Predict an 182.79% Upside in Assertio (ASRT): Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNS3BIODJMd2pmVzNWVW9nbFQ3MHB2UVJzZVVvelVkVFVhWm1NNk4tX1lJQ01aRndDVGl1YU1CZmJUQkx5cVllcEFDU1c4eGNFTTZoN0JjMlpLRXM4SUlJWFA2U1F5UnQ3MnpQdzhuWnBHLVdpSjJZZ2swN0hWZFcxYVl1THAxX0RDWUx5a3N0cXRfeDUxUGQwNkdfaWFIdjVxZGF1SWVrMmlkdGNhdmt0VndDNnRXUTJFU0hKYnlIb0RMclRJZFdKNA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNaHpUbDVEVVZJX050MVVoMDRaSU94SF9aVkRoRnhjUnFGbUhaZ2V6WE15VFVZRXBpRGlRa2FIQlo2YUxEWUJtQXdlZ0ZqQTVaNDItUTVTaU5qa29paEJiV01QMS1OR3J2cE9mTl9xTDBxd1lKbFYxYjc5a0ZlZ2lWWWwxNlpTeTNxdkg5bF9PNm5iZTRNNmNaZ0ZzODB6V2oyVU5CZQ?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncology push at Assertio: chasing up to $125M in 2026 sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQSjBKRU5rX09IVkZoekdJR1VWR0VodmxUYmpJZXdsTXhpbTVjT1lmekNIeXo0Y2d3a3Y0eDZJeHNTSzVGS05EQ2hXRWJCMUpDY2RNMDFGVHRPVlRoWXVqTzhFWWJfd29KRDdTLUtndFdsajZ6MEhna0xaZnhaOFB3YVN2Q0NEX3hJTGk4bkVsWEhKSndWaWZRVXhsS1JjY0FuQlM1UzMxOVY0cGw2VEt6dmZObkVYZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPZjFFWjVHd2N2UkgwdWdWMnRIS1VCRXczNlF5X1JZckZZdDF5TXJSMTNlMEVxUjdraWF3eDFwNGUyczNRd0ZyNW5hN3ZqSFBZNThpOW1uaUlDZXEzYmZpUkNFc0xQaFB1RzFOQUFyNTBKaTFzdlRLbWQtTjRVVEhEbA?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Assertio Holdings (ASRT) Narrative Is Shifting Around A Steady 37.44 Fair Value Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNUkF3NFJmWms2NzA3YVdmaWpqWEdKNlAxamdjQ0xKaDBWRDdRWFc4ek5sOFZhNXdwVmJLOGR3MGFJYUVsazJOUVExMzE1N091N3NFd0hWendRUEg2b2tBODVXbnVaMk5KNWJ5ZVlZNkhMczJtMEppWTNXM01reTJmZEg5a09xeUhtQnNCR1FiVmE?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA appoints first-ever Chief AI Officer; the first at-home HPV test for cervical cancer screening is approved; Assertio to pay $3.6M for illegally marketing fentanyl spray beyond approved use \u2013 Morning Medical Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Medical Economics", "published_at": "2025-05-12T07:00:00+00:00", "published_display": "12 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings (ASRT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBFUDBlUkRUdEpXeHR3TzFLVTN2YnhoQnZvS21LTjc5djRXR1lvcjE3dm1LallDb1pwdGN0cTIweEh0UW50THhxVHpuWWd1aGk0a0Rj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T18:27:15+00:00", "published_display": "24 Apr 2025 18:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Completed Merger with Zyla Life Sciences", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxON0tXSUR4VFF3dFpMZVROVlU4MGc2bmRCVGxFSE56dGViZDV4R0VocjJCT0JZTzgwMktIZmltNFZEcVdYZlNxNUpKTjU4dWJjWllHMHBxNkRFRF9nNEp0WlBIbm5ZWkdod2R4aGZuendWZEV2c2JTdVl2Mk9NUkt2bFdwTC1CMFNzY3dMTWJZMTByMW9qb3NmYjltWDg0NXVicU1YeXlPRUY?oc=5", "source_name": "PR Newswire", "published_at": "2020-05-20T07:00:00+00:00", "published_display": "20 May 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Therapeutics Agrees to Merge with Zyla Life", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAJBVV95cUxNZS1LYVMtdW14R29OSUJsRGNSbXZpZW52V3JHcndldU5VeGhQY3Y2bFNpWXQ0dUpmNEYzY1FMYUpKOENaSkVOU2hmanZrMFRHcVRwTkVyaWdOQlZ2NmhlQzZVVFlHXzdJbnMxYzE3dmUzWjdydjlSR3c4QUVyUmtmQVpBNDQ2MFJhRHgyS3ljQWdObFAwR0FzRmZpYW14Q0pwemVkVVpmM2lqVHV1RUdwcFlTWUNKLXllWURCR2FjdnpHcjd3NFRLOVQ1WmVTcjg2dVdYTXF6TDBEel9YRTduTW85bFMzZ1FXN19NMzJCN2hIN1NsQ2tyNnE1d1BWd2xSaHRmTG0xMjBZYjVXTm5wMmZHRXc5Qk1Yd2RiWDZiamsyYkFmR09acU9PTWpGOXdp?oc=5", "source_name": "GlobeNewswire", "published_at": "2020-03-16T07:00:00+00:00", "published_display": "16 Mar 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Press Release: Assertio Provides Update on Garda Therapeutics Tender Process", "summary": "Assertio Holdings, Inc. announced an update regarding the tender offer for all outstanding shares of Garda Therapeutics Inc. The tender offer period, which began on March 29, 2023, has been extended several times and is now set to expire on July 24, 2026. As of July 10, 2026, app", "url": "https://www.moomoo.com/news/post/68640102/press-release-assertio-provides-update-on-garda-therapeutics-tender-process?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T07:11:51", "published_display": "13 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Small-Cap Growth Virtual Investor Conference Summary", "summary": "This summary details Assertio Holdings Inc.'s financial performance and strategic outlook discussed at the Small-Cap Growth Virtual Investor Conference on February 1, 2026. The company reported strong Q1 financials, reaffirmed its 2024 guidance, and highlighted Rolvedon as its pr", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-small-cap-growth-virtual-investor-conference_onXvfO3d", "source_name": "Quartr", "published_at": "2026-07-11T00:39:37", "published_display": "11 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Proxy Filing Summary", "summary": "Assertio (ASRT) has released a summary of its Proxy Filing for an Annual Meeting scheduled for May 7, 2025. Key topics for the meeting include the election of seven directors, approval of an amendment to the 2014 Omnibus Incentive Plan, an advisory vote on executive compensation,", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-proxy-filing_onXvqJZF", "source_name": "Quartr", "published_at": "2026-07-10T17:10:55", "published_display": "10 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Maxim Group\u2019s 2024 Healthcare Virtual Summit Summary", "summary": "This article summarizes Assertio's (ASRT) presentation at Maxim Group\u2019s 2024 Healthcare Virtual Summit, highlighting the company's strategic shift from a broad portfolio to a focus on 7 key assets, with Rolvedon as the primary growth driver. Assertio aims to expand Rolvedon's mar", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-maxim-group-s-2024-healthcare-virtual-summit_onXvfEB8", "source_name": "Quartr", "published_at": "2026-07-09T00:39:37", "published_display": "09 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Q4 2025 earnings summary", "summary": "Assertio (ASRT) reported its Q4 and full-year 2025 earnings, exceeding guidance for net product sales and adjusted EBITDA under new leadership. The company is refocusing on ROLVEDON as its core growth asset, completing its integration and optimizing commercial infrastructure for ", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-q4-2025_onXvqPnY", "source_name": "Quartr", "published_at": "2026-07-09T00:39:37", "published_display": "09 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Q1 2026 earnings summary", "summary": "Assertio (ASRT) reported its Q1 2026 earnings, detailing the sale of non-ROLVEDON assets for $35M and a merger agreement with Garda Therapeutics. The company experienced a significant revenue decline to $9.9M, leading to a net loss of $18.9M, primarily due to lower ROLVEDON and I", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-q1-2026_onXvnkCb", "source_name": "Quartr", "published_at": "2026-07-09T00:39:37", "published_display": "09 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 26, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Q4 2024 earnings summary", "summary": "Assertio (ASRT) reported its Q4 and full-year 2024 earnings, highlighting a stabilization year with Rolvedon sales exceeding $60 million and optimized portfolio management resulting in over $26 million in operating cash flow. The company strengthened its balance sheet and made le", "url": "https://quartr.com/events/assertio-holdings-inc-asrt-q4-2024_onXvfBGz", "source_name": "Quartr", "published_at": "2026-07-08T12:10:55", "published_display": "08 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings (NASDAQ: ASRT) common stock struck from Nasdaq list", "summary": "Assertio Holdings, Inc. (ASRT) common stock has been removed from listing and registration on the Nasdaq Stock Market LLC, as indicated by a Form 25 SEC filing. This voluntary withdrawal means the exchange and issuer complied with rules governing such removal due to Section 12(b)", "url": "https://www.stocktitan.net/sec-filings/ASRT/25-nse-assertio-holdings-inc-sec-filing-53b125ecbd98.html", "source_name": "Stock Titan", "published_at": "2026-07-07T14:39:53", "published_display": "07 Jul 2026 14:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Deadline Alert", "summary": "Faruqi & Faruqi, LLP is investigating potential claims against Assertio Holdings, Inc. (NASDAQ: ASRT) and reminds investors of a March 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Assertio made false or", "url": "https://www.newsfilecorp.com/release/196039/Assertio-Deadline-Alert?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-07T11:40:39", "published_display": "07 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASRT CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds Assertio Holdings, Inc. (ASRT) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm", "summary": "Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against Assertio Holdings, Inc. (NASDAQ: ASRT), citing violations of federal securities laws due to alleged omissions and fraudulent misrepresentations. The lawsuit stems from significant stock price d", "url": "https://www.newsfilecorp.com/release/195846/ASRT-CLASS-ACTION-NOTICE-Kessler-Topaz-Meltzer-Check-LLP-Reminds-Assertio-Holdings-Inc.-ASRT-Shareholders-of-Securities-Fraud-Class-Action-Lawsuit-and-Encourages-Investors-with-Substantial-Losses-to-Contact-the-Firm?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-05T11:10:57", "published_display": "05 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Lifesciences Completes Acquisition of Assertio Holdings", "summary": "Zydus Lifesciences has successfully completed its tender offer for the acquisition of Assertio Holdings Inc., marking a strategic expansion into the US pharmaceutical market. Assertio shareholders received $23.50 per share in cash, and Assertio will become a wholly-owned subsidia", "url": "https://themachinemaker.com/zydus-lifesciences-completes-acquisition-of-assertio-holdings/", "source_name": "Machine Maker", "published_at": "2026-06-29T20:40:08", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[15-12G] Assertio Holdings, Inc. SEC Filing", "summary": "Assertio Holdings, Inc. has filed Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports under Sections 13 and 15(d). The filing, dated June 26, 2026, was s", "url": "https://www.stocktitan.net/sec-filings/ASRT/15-12g-assertio-holdings-inc-sec-filing-dbe79f6fbba2.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:40:49", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Assertio Holdings, Inc. SEC Filing", "summary": "This article reports on an SEC filing (Form EFFECT) by Assertio Holdings, Inc. (ASRT), which received a neutral impact and sentiment rating. The filing indicates an effectiveness date of June 17, 2026, for a Notice of Effectiveness related to access number 0001104659-26-074620. A", "url": "https://www.stocktitan.net/sec-filings/ASRT/effect-assertio-holdings-inc-sec-filing-572d5f4cf6f1.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:59", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus\u2019s acquisition of Assertio to bolster its specialty pharma presence in US market", "summary": "Zydus Lifesciences Ltd. has completed its cash tender offer to acquire U.S.-based Assertio Holdings, Inc. for $23.50 per share. Upon finalization, Assertio will become a wholly-owned subsidiary of Zydus and will be delisted from Nasdaq. This acquisition aims to strengthen Zydus' ", "url": "https://www.indianpharmapost.com/news/zyduss-acquisition-of-assertio-to-bolster-its-specialty-pharma-presence-in-us-market-20664", "source_name": "Indian Pharma Post", "published_at": "2026-06-20T05:09:42", "published_display": "20 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings Inc (ASRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article details the revenue breakdown for Assertio Holdings Inc (ASRT), providing insights into its performance by business segment and geographical region. The company's revenue streams are primarily driven by products like ROLVEDON, INDOCIN, and Sympazan, with the United S", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asrt/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:12", "published_display": "18 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings Inc (ASRT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Assertio Holdings Inc (ASRT), listing major institutional shareholders like Nantahala Capital Management and Opaleye Management, along with their respective holdings. It also breaks down shareholder types, institutional shareholdi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asrt/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T13:10:12", "published_display": "18 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings Inc (ASRT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Assertio Holdings Inc (ASRT), noting its current earnings forecast score, average price target of $3.00, and analyst ratings. It also includes a peer comparison and answers FAQs regarding revenue expectations, price targets, recent EP", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asrt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:12", "published_display": "18 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Completes USD 166.4 Million Acquisition of US-Based Assertio Holdings", "summary": "Zydus Lifesciences has completed its acquisition of US-based Assertio Holdings Inc. for $166.4 million. Through its wholly-owned subsidiary, Zara Merger Sub Inc, Zydus successfully concluded the cash tender offer for all outstanding shares of Assertio. As a result, Assertio is no", "url": "https://medicaldialogues.in/amp/news/industry/pharma/zydus-completes-usd-1664-million-acquisition-of-us-based-assertio-holdings-173050", "source_name": "Medical Dialogues", "published_at": "2026-06-17T16:06:00", "published_display": "17 Jun 2026 16:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) director fully cashes out shares and options in Zydus $23.50-per-share merger", "summary": "Assertio Holdings, Inc. director William McKee has fully disposed of his equity, including 27,936 shares of common stock and two stock option grants, as part of the company's cash sale to Zydus. A Zydus subsidiary acquired all outstanding Assertio shares at $23.50 per share, lead", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-36675b4dbec9.html", "source_name": "Stock Titan", "published_at": "2026-06-17T15:39:52", "published_display": "17 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) director cashes out shares and options in Zydus merger", "summary": "Assertio Holdings director Heather L. Mason has disposed of all her equity in Assertio following its merger with Zydus entities. Her common shares and eligible stock options were cashed out at $23.50 per share through a tender offer that became effective on June 16, 2026. The For", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-1755c56833ac.html", "source_name": "Stock Titan", "published_at": "2026-06-17T04:40:26", "published_display": "17 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus buys Assertio (ASRT); EVP Schlessinger equity cashed out at $23.50", "summary": "Assertio Holdings, Inc.'s EVP and General Counsel, Sam Schlessinger, cashed out all his equity, including common shares, stock options, and restricted stock units, as part of the company's merger with Zydus Worldwide DMCC. Zydus successfully completed a tender offer for Assertio'", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-13f82ad09665.html", "source_name": "Stock Titan", "published_at": "2026-06-17T04:10:14", "published_display": "17 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) COO exits stock, options and RSUs in $23.50-per-share cash merger", "summary": "Assertio Holdings, Inc.'s President and COO, Paul Schwichtenberg, reported the disposition of his equity awards following the company's merger with Zydus entities. The merger, which made Assertio a wholly-owned subsidiary, involved a tender offer where all common shares were acqu", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-ee569b458752.html", "source_name": "Stock Titan", "published_at": "2026-06-17T02:35:33", "published_display": "17 Jun 2026 02:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO Ajay Patel exits Assertio (ASRT) stake in $23.50-per-share merger", "summary": "Assertio Holdings, Inc. CFO Ajay Patel has exited all his equity holdings in the company, including 15,942 common shares and various stock options and restricted stock units, as part of Assertio's cash merger with Zydus entities. The merger involved a tender offer of $23.50 per s", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-24d25004d068.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:34", "published_display": "16 Jun 2026 22:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) director\u2019s shares and options cashed out in $23.50 Zydus buyout", "summary": "Assertio Holdings, Inc. director Sravan Kumar Emany reported that all his equity in the company, including 23,855 shares and various stock options, was cashed out as part of Assertio's merger with Zydus Worldwide DMCC. The common shares were disposed of at the tender offer price ", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-cb24c71f5837.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:34", "published_display": "16 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) CEO exits all shares and awards in $23.50-per-share cash merger", "summary": "Assertio Holdings, Inc. CEO Mark L. Reisenauer disposed of all his equity interests in connection with Assertio\u2019s cash merger with an affiliate of Zydus. A tender offer acquired all outstanding Assertio common shares at $23.50 per share in cash, resulting in the cancellation and ", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-f1857afd104f.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:34", "published_display": "16 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings (ASRT) director exits as Zydus cash merger pays $23.50", "summary": "Assertio Holdings director Kirk Sigurd has disposed of all his equity in the company following its merger with Zydus. His 12,017 common shares were converted to cash at $23.50 per share, and all stock options were either cashed out or cancelled according to the merger terms. This", "url": "https://www.stocktitan.net/sec-filings/ASRT/form-4-assertio-holdings-inc-insider-trading-activity-ce2fe455261e.html", "source_name": "Stock Titan", "published_at": "2026-06-16T22:39:34", "published_display": "16 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acquirer completes Assertio deal; ASRT removed registered shares after $23.50 tender", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNNmJzczdSakpsUUsyN1VrTk1TRUh2UW9mMkdIZjd3VWUtelVxX0wzSVF5dGRGelBuQ2tqRy13RFVCSHo4LTRBejZ6MUJMQUZZSDExdDZ0RE1vc1g1OGtPVlpMZVc5d2VQQ2xuWTUwZE93WENRZkFxMHNud3ZVYk5QQWhiQy1fQVpaeFhUWlR0RlZKdGdldWZncVdrNXlHdzh2Ympv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus deal gives Assertio holders $23.50 cash per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQcEVxME5CMUt6c3kzZ3FZU3NkWEpxalhncXB1N0ZmOUV6dlBxVExuLURqNVJ6UEt5aFR6Vm52TmhCLUVoS3FWaGhVNGNCXzM0S1dJY1hDcmRRc2hSLWgzYk9MY3hVbi00WVBkQWU1U2RYeG1aYl9RSk5vaEY0Q1ZIOEpDS2JnVDNzbFZhcXlDREZsdmZDNE44a2wwbmo0bFNlNjg5NzdQaEE3ZS1XVG4yLU5tajBJc2czVTMyQzdRVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Lifesciences (NASDAQ: ASRT) completes $23.50-per-share tender offer", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPLVhFUTZLT2xnTHdGdWU5enVxaUNzUldTbFdnNzAwWG53QkhHbWFWbnFTOWJlYWVrc1RVa1g4N3pFZ25YRkZ2Z0p4OUJLM0RVbDBlZGpXT3dvZEhaYklLcUpHUldJTzVPeUZZSGpxLUtGYmVONm12bkdJVmJmZ1JEeVEzRHEwbl9pclljMGY3OGgtVE5sMHp1T2NPMzRfTDBqUHRsT2EyYUFDZVZpUEdoOU94dHJxZ2ktMURRaFIzQnVRT3It?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio investors get 75.8% premium in $166.4M Zydus buyout", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcUJlMFczWTZKZzlhS25Wbnp4Wkl1bVRRQVBLTGJOYnQ0cVdsc0NKZnJIdVNsOXBQUW4tS1R3QUQzSmlaaWhtcEwtUmx2bHpUa0t6WEswTm9LWlRqUnp2VzE4Z1ZCZ3BOaW5wbFp5SGxnMGg0YkM2WVk3RFVKNVgyUVZIcUI2OGtHUHRNOTBtRXdIRDIxd1ZSTUpNTGFYUlRJVHd2a2pBSVI4Z0owSUVxdXc4cXdxQ01TaXVkTkRvcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOTDdvdTNTZG0zWmQxT0h2Ql9TNmo5UDk1ZVRnQVVZTHBHOGd3QmhpYlNRVVlmajladmFxV1ZLU091b1JWNzEwaWEtcEdwaGNKaV94cGEwbWw2cmJGU3c2TEdfRWJvQTFYV3N3RE1DaWV3TzhJTmdIUGZWa1YtOVJQQ2NXV3dxS3J5aUNQdndHd24zdE0?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Assertio (ASRT) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOVFlPU01VamJXTmJXcU9MREJRLTVOaXBKWkh5MEdURFhLZ25ONHNHWkUzd0M4aDJaUFhOajR0OTlzbmVuSmZ2WDRnYjVYcS01NXltRjh3eENqM0pHUXlOck5WRDZjRFJsU3VOU1lXOU9MSFBwb0QxVm1ENkpUZE41SEdzRWlROUM3YXU3ZW1UWjdGYnkwSzRnRmFGblZoNFRCODhV?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Assertio Holdings (ASRT) Story Is Shifting With The Takeover And Reset Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPekRyMkNaU3VIaXIyZmlIQzRQVFI4NjMtREdzQmhMSmg5REpfOW5fd1FaOFdncWxLWVFuM21DRk5GeHJJelNpMjhXaE5JTmIyWWRkUjdOOW5WTmMwQncxOW1XTDRtT1hzOXhfTFp5NktZUHZtOTdLRHBlaG4yQzJkSGVJTnNLZmMxb21XWUFHNUJJNWJxTlNtdEFSSTRWbU5uOGxaUA?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASRT Stock Alert: Halper Sadeh LLC is Investigating Whether Assertio Holdings, Inc. is Obtaining a Fair Price for its Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxQQlF1MnhTZ0IzNTJleDlSNWVDaGM3MUtXXzFDOUszYlNEa0M1NFVoVTJCamF2UVlJMlcwOXprTXRzS1VLX21fSXd2WWZYTW5Mc01oSlZwVnB1SVFNcFlpbV94Vm12U1pBYzdoVm5EX0Y1WE5wS0RmNUFkWTMtdTF3bXhfY2M0cmFIZnBQb1l2WjFBUHBaQXJJTGU5NDdwVGd2bDRZMGUyV0cxUTd5TnNFdEF1NXpEQmlyXzJtdHZHY0ZRamZzdUFod2ZVcjlDc2pmaEZMbmVnR2I1MFdoQVJUeGhEMjkxM0I0Z0VOWE9tWl9FWVBwNHNONjQ3MDdobUpNVWZvNXptVFBJVmZYeWdKdGhWaw?oc=5", "source_name": "Business Wire", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQTXA2dnNQYU5aOXVJYUVBQ2g3OC0weldPMkMwYmpTemZKSlVvTVdhT2JkT0lyMDNybzFvb0M0UGpNTnd0dXotNjUwNWNoR2Y5RVV4WTRodFFOTFBhMzgwOVVLTmpvTXNTTFNEM0pVaHR0SndJbkFTd2paYzdGVXZWMm5qMzlxbllGa2paVUtlT2xRdW55UHJ4QlJGSTBuUWRf?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street cuts Assertio stock rating on acquisition deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPU1NIWFh6ZU1SQWsteEotM1Z2bHZ6RFZEcmk0cXgwVlJDWkZBQWtSVUNqcXdFYmxybk92UXVpYUdVOHR4QTZLZFJ2QXJWa2lTTHo4TXBoTXJ2aWNXM2U4alNUUVgtanlpZFVFQWE0SWdtMzZmeTU5aHhFTmJUR2VWREFHeXBRYnYzVDRJRmlLRTg2SUNER0lCYmp0czJoZ2QtMWNIUnJkM0tFdG5wdkhJeFd3Tlh3bnlvS2c?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Assertio stock rating on Garda acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxONVYzZEl1eFEyRENwMVFJQWowY2dMUnVtczA5alpYN0l4dzZ0WDVlRjdiOEJWSjRTcUEyRFp1SFVOZEt4QVk0R3BRMVdXZjlRTWpZNHZVZkV1N0xiRGY4bnRBdFNvel9wVTJGY0ZDWEJOb3VGakFQU3pfVlRsakpXNERZWDYteTRjLXh4RWxyUUJMRXFCdEJ4MUl3b29hR09uejRkTDBGRWI3STZiZVpOOXRqVlVRcHpQd3V2R0ZB?oc=5", "source_name": "Investing.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings (ASRT) Issues 2026 Sales Guidance After Wider 2025 Losses Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQSjBFNWZtTkZyYXBqa2lVd3Bkem1IOC1xTE4zUUV1U2d0Sm1NdjZlQWtUdkZWRGN4Z0xtWHU0RmVUQXZDVVVjaW1JbjNFZ1NfNUdyMmJqeHN0Y2ljWEpzR3ZscnN4ZVBKRHdwMU54T1JXcExsOVlwS2Eya0RtOGE5UE9Cb1Jxam1fbWVRSFpsb3dqbTd0Ni1fREZ4YWNzRVJ3?oc=5", "source_name": "Market source", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPcFoyZ3BkOXZubThKZk1KeWNxaEpSVUdfZkN0TWIxX2lvbnVhY0lGQkNvNzRVUm4yOXJpMU9pQ3VjYzdFYUI1QmpEaEJsSmRfSjFFQ2ZFVi1OSWtmdGZmREI1WFdqQ2RKMWV0dDdxNzlWODJvSnhERzN4dGRheUs3cExQWm5OX2xGTlZXWDNhZ2owNDlz?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Predict an 182.79% Upside in Assertio (ASRT): Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNS3BIODJMd2pmVzNWVW9nbFQ3MHB2UVJzZVVvelVkVFVhWm1NNk4tX1lJQ01aRndDVGl1YU1CZmJUQkx5cVllcEFDU1c4eGNFTTZoN0JjMlpLRXM4SUlJWFA2U1F5UnQ3MnpQdzhuWnBHLVdpSjJZZ2swN0hWZFcxYVl1THAxX0RDWUx5a3N0cXRfeDUxUGQwNkdfaWFIdjVxZGF1SWVrMmlkdGNhdmt0VndDNnRXUTJFU0hKYnlIb0RMclRJZFdKNA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNaHpUbDVEVVZJX050MVVoMDRaSU94SF9aVkRoRnhjUnFGbUhaZ2V6WE15VFVZRXBpRGlRa2FIQlo2YUxEWUJtQXdlZ0ZqQTVaNDItUTVTaU5qa29paEJiV01QMS1OR3J2cE9mTl9xTDBxd1lKbFYxYjc5a0ZlZ2lWWWwxNlpTeTNxdkg5bF9PNm5iZTRNNmNaZ0ZzODB6V2oyVU5CZQ?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncology push at Assertio: chasing up to $125M in 2026 sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQSjBKRU5rX09IVkZoekdJR1VWR0VodmxUYmpJZXdsTXhpbTVjT1lmekNIeXo0Y2d3a3Y0eDZJeHNTSzVGS05EQ2hXRWJCMUpDY2RNMDFGVHRPVlRoWXVqTzhFWWJfd29KRDdTLUtndFdsajZ6MEhna0xaZnhaOFB3YVN2Q0NEX3hJTGk4bkVsWEhKSndWaWZRVXhsS1JjY0FuQlM1UzMxOVY0cGw2VEt6dmZObkVYZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPZjFFWjVHd2N2UkgwdWdWMnRIS1VCRXczNlF5X1JZckZZdDF5TXJSMTNlMEVxUjdraWF3eDFwNGUyczNRd0ZyNW5hN3ZqSFBZNThpOW1uaUlDZXEzYmZpUkNFc0xQaFB1RzFOQUFyNTBKaTFzdlRLbWQtTjRVVEhEbA?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Assertio Holdings (ASRT) Narrative Is Shifting Around A Steady 37.44 Fair Value Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNUkF3NFJmWms2NzA3YVdmaWpqWEdKNlAxamdjQ0xKaDBWRDdRWFc4ek5sOFZhNXdwVmJLOGR3MGFJYUVsazJOUVExMzE1N091N3NFd0hWendRUEg2b2tBODVXbnVaMk5KNWJ5ZVlZNkhMczJtMEppWTNXM01reTJmZEg5a09xeUhtQnNCR1FiVmE?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA appoints first-ever Chief AI Officer; the first at-home HPV test for cervical cancer screening is approved; Assertio to pay $3.6M for illegally marketing fentanyl spray beyond approved use \u2013 Morning Medical Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Medical Economics", "published_at": "2025-05-12T07:00:00+00:00", "published_display": "12 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Holdings (ASRT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBFUDBlUkRUdEpXeHR3TzFLVTN2YnhoQnZvS21LTjc5djRXR1lvcjE3dm1LallDb1pwdGN0cTIweEh0UW50THhxVHpuWWd1aGk0a0Rj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T18:27:15+00:00", "published_display": "24 Apr 2025 18:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Completed Merger with Zyla Life Sciences", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxON0tXSUR4VFF3dFpMZVROVlU4MGc2bmRCVGxFSE56dGViZDV4R0VocjJCT0JZTzgwMktIZmltNFZEcVdYZlNxNUpKTjU4dWJjWllHMHBxNkRFRF9nNEp0WlBIbm5ZWkdod2R4aGZuendWZEV2c2JTdVl2Mk9NUkt2bFdwTC1CMFNzY3dMTWJZMTByMW9qb3NmYjltWDg0NXVicU1YeXlPRUY?oc=5", "source_name": "PR Newswire", "published_at": "2020-05-20T07:00:00+00:00", "published_display": "20 May 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assertio Therapeutics Agrees to Merge with Zyla Life", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAJBVV95cUxNZS1LYVMtdW14R29OSUJsRGNSbXZpZW52V3JHcndldU5VeGhQY3Y2bFNpWXQ0dUpmNEYzY1FMYUpKOENaSkVOU2hmanZrMFRHcVRwTkVyaWdOQlZ2NmhlQzZVVFlHXzdJbnMxYzE3dmUzWjdydjlSR3c4QUVyUmtmQVpBNDQ2MFJhRHgyS3ljQWdObFAwR0FzRmZpYW14Q0pwemVkVVpmM2lqVHV1RUdwcFlTWUNKLXllWURCR2FjdnpHcjd3NFRLOVQ1WmVTcjg2dVdYTXF6TDBEel9YRTduTW85bFMzZ1FXN19NMzJCN2hIN1NsQ2tyNnE1d1BWd2xSaHRmTG0xMjBZYjVXTm5wMmZHRXc5Qk1Yd2RiWDZiamsyYkFmR09acU9PTWpGOXdp?oc=5", "source_name": "GlobeNewswire", "published_at": "2020-03-16T07:00:00+00:00", "published_display": "16 Mar 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 84, "total_relevant": 48, "sentiment_summary": {"positive": 12, "negative": 7, "neutral": 29, "score": 51, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 74, "events": [{"event": "general", "label": "Market update", "weight": 10.8, "count": 19}, {"event": "deals", "label": "Deals and strategy", "weight": 9.35, "count": 17}, {"event": "earnings", "label": "Earnings", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 12, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 23.5, "latest_week": "2026-06-19", "one_week_move": 0.1, "four_week_move": 0.3, "twelve_week_move": 21.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.52777, "market_dynamics_buy_signal": false, "relative_strength": 42.193067, "fair_value_gap": 25.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 42.9115, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +0.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 47, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 17}, {"label": "Market source", "count": 9}, {"label": "Quartr", "count": 6}, {"label": "TradingKey", "count": 3}, {"label": "TMX Newsfile", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "Moomoo", "count": 1}, {"label": "Machine Maker", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 19}, {"label": "Deals and strategy", "count": 17}, {"label": "Earnings", "count": 5}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +0.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Press Release: Assertio Provides Update on Garda Therapeutics Tender Process"}], "updated_at": "2026-07-16T15:24:28.333790+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}